SYT-SSX breakpoint peptide vaccines in patients with synovial sarcoma: A study from the Japanese Musculoskeletal Oncology Group 19

Cancer Science

Volumn 103, Issue 9, 2012, Pages 1625-1630

  Kawaguchi, Satoshi ^a   Tsukahara, Tomohide ^a   Ida, Kazunori ^a   Kimura, Shigeharu ^a   Murase, Masaki ^a   Kano, Masanobu ^a   Emori, Makoto ^a   Nagoya, Satoshi ^a   Kaya, Mitsunori ^a   Torigoe, Toshihiko ^a   Ueda, Emiri ^a   Takahashi, Akari ^a   Ishii, Takeshi ^b   Tatezaki, Shin ichiro ^b   Toguchida, Junya ^c   Tsuchiya, Hiroyuki ^d   Osanai, Toshihisa ^e   Sugita, Takashi ^f   Sugiura, Hideshi ^g   Ieguchi, Makoto ^h   Ihara, Koichiro ⁱ   Hamada, Ken ichiro ^j   Kakizaki, Hiroshi ^k   Morii, Takeshi ^l   Yasuda, Taketoshi ^m   Tanizawa, Taisuke ⁿ   Ogose, Akira ^o   Yabe, Hiroo ^p   Yamashita, Toshihiko ^a   Sato, Noriyuki ^a   Wada, Takuro ^a   more..

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CHIBA CANCER CENTER   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d KANAZAWA UNIVERSITY   (Japan)

^e YAMAGATA UNIVERSITY   (Japan)

^f HIROSHIMA PREFECTURAL HOSPITAL   (Japan)

^g AICHI CANCER CENTER HOSPITAL   (Japan)

^h Osaka Prefecture University   (Japan)

ⁱ Kanmon Medical Center   (Japan)

^j OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^k HIROSAKI NATIONAL HOSPITAL   (Japan)

^l KYORIN UNIVERSITY   (Japan)

^m UNIVERSITY OF TOYAMA   (Japan)

ⁿ CANCER INSTITUTE HOSPITAL   (Japan)

^o NIIGATA UNIVERSITY   (Japan)

^p KEIO UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; GLYCYLTYROSYLASPARTYLGLUTAMINYLISOLEUCYLMETHIONYLPROLYLISOLEUCYLLYSINE; GLYCYLTYROSYLASPARTYLGLUTAMINYLISOLEUCYLMETHIONYLPROLYLLYSYLLYSINE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN HEMORRHAGE; CANCER IMMUNIZATION; CLINICAL ARTICLE; CLINICAL PROTOCOL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HUMAN; LUNG METASTASIS; MALE; PRIORITY JOURNAL; SYNOVIAL SARCOMA;

ADULT; AGED; CANCER VACCINES; FEMALE; HLA-A ANTIGENS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; SARCOMA, SYNOVIAL; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME; VACCINES, SUBUNIT; YOUNG ADULT;

EID: 84865737472     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02370.x     Document Type: Article

References (42)

1. Eilber FC, Dry SM. Diagnosis and management of synovial sarcoma. J Surg Oncol 2008; 97: 314-20.
2. Fisher C. Soft tissue sarcomas with non-EWS translocations: molecular genetic features and pathologic and clinical correlations. Virchows Arch 2010; 456: 153-66.
3. Ferrari A, Bisogno G, Alaggio R et al. Synovial sarcoma of children and adolescents: the prognostic role of axial sites. Eur J Cancer 2008; 44: 1202-9.
4. Italiano A, Penel N, Robin YM et al. Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group. Ann Oncol 2009; 20: 425-30.
5. Palmerini E, Staals EL, Alberghini M et al. Synovial sarcoma: retrospective analysis of 250 patients treated at a single institution. Cancer 2009; 115: 2988-98.
6. Sultan I, Rodriguez-Galindo C, Saab R, Yasir S, Casanova M, Ferrari A. Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology, and End Results program, 1983 to 2005: an analysis of 1268 patients. Cancer 2009; 115: 3537-47.
7. Brennan B, Stevens M, Kelsey A, Stiller CA. Synovial sarcoma in childhood and adolescence: a retrospective series of 77 patients registered by the Children's Cancer and Leukaemia Group between 1991 and 2006. Pediatr Blood Cancer 2010; 55: 85-90.
8. Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 2008; 8: 351-60.
9. Finn OJ. Cancer immunology. N Engl J Med 2008; 358: 2704-15.
10. Khazaie K, Bonertz A, Beckhove P. Current developments with peptide-based human tumor vaccines. Curr Opin Oncol 2009; 21: 524-30.
11. Perez SA, von Hofe E, Kallinteris NL et al. A new era in anticancer peptide vaccines. Cancer 2010; 116: 2071-80.
12. Pollack SM, Loggers ET, Rodler ET, Yee C, Jones RL. Immune-based therapies for sarcoma. Sarcoma 2011; 2011: 438940.
13. Sato Y, Nabeta Y, Tsukahara T et al. Detection and induction of CTLs specific for SYT-SSX-derived peptides in HLA-A24(+) patients with synovial sarcoma. J Immunol 2002; 169: 1611-8.
14. Ida K, Kawaguchi S, Sato Y et al. Crisscross CTL induction by SYT-SSX junction peptide and its HLA-A*2402 anchor substitute. J Immunol 2004; 173: 1436-43.
15. Kawaguchi S, Wada T, Ida K et al. Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma. J Transl Med 2005; 3: 1.
16. Tsukahara T, Kawaguchi S, Torigoe T et al. Prognostic impact and immunogenicity of a novel osteosarcoma antigen, papillomavirus binding factor, in patients with osteosarcoma. Cancer Sci 2008; 99: 368-75.
17. Tsukahara T, Kawaguchi S, Torigoe T et al. HLA-A*0201-restricted CTL epitope of a novel osteosarcoma antigen, papillomavirus binding factor. J Transl Med 2009; 7: 44.
18. Bailly F, Mattei A, SiAhmed SN, Trepo C. Uncommon side-effects of interferon. J Viral Hepat 1997; 4 (Suppl 1): 89-94.
19. Niederwieser G, Bonelli RM, Kammerhuber F, Reisecker F, Koltringer P. Intracerebral haemorrhage under interferon-beta therapy. Eur J Neurol 2001; 8: 363-4.
20. Nishiofuku M, Tsujimoto T, Matsumura Y et al. Intracerebral hemorrhage in a patient receiving combination therapy of pegylated interferon alpha-2b and ribavirin for chronic hepatitis C. Intern Med 2006; 45: 483-4.
21. Dourakis SP, Deutsch M, Hadziyannis SJ. Immune thrombocytopenia and alpha-interferon therapy. J Hepatol 1996; 25: 972-5.
22. Yamane A, Nakamura T, Suzuki H et al. Interferon-alpha 2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes. Blood 2008; 112: 542-50.
23. Cervera A, Amaro S, Chamorro A. Oral anticoagulant-associated intracerebral hemorrhage. J Neurol 2012; 259: 212-24.
24. Mantha S, Pianka AM, Tsapatsaris N. Determinants of intracranial hemorrhage incidence in patients on oral anticoagulation followed at the Lahey clinic. J Thromb Thrombolysis 2011; 32: 334-42.
25. + T cell numbers, effector function, and antitumor activity. J Immunol 2009; 182: 7398-407.
26. + T-cell responses. J Clin Oncol 2003; 21: 1562-73.
27. Di Pucchio T, Pilla L, Capone I et al. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Cancer Res 2006; 66: 4943-51.
28. Amato RJ, Shingler W, Goonewardena M et al. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial. J Immunother 2009; 32: 765-72.
29. Whelan J, Patterson D, Perisoglou M et al. The role of interferons in the treatment of osteosarcoma. Pediatr Blood Cancer 2010; 54: 350-4.
30. Brodowicz T, Wiltschke C, Kandioler-Eckersberger D et al. Inhibition of proliferation and induction of apoptosis in soft tissue sarcoma cells by interferon-alpha and retinoids. Br J Cancer 1999; 80: 1350-8.
31. Jain N, Reuben JM, Kantarjian H et al. Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. Cancer 2009; 115: 3924-34.
32. Dagher R, Long LM, Read EJ et al. Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Med Pediatr Oncol 2002; 38: 158-64.
33. Cathcart K, Pinilla-Ibarz J, Korontsvit T et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 2004; 103: 1037-42.
34. Bocchia M, Gentili S, Abruzzese E et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 2005; 365: 657-62.
35. Rojas JM, Knight K, Wang L, Clark RE. Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia 2007; 21: 2287-95.
36. Bocchia M, Defina M, Aprile L et al. Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination. Nat Rev Clin Oncol 2010; 7: 600-3.
37. Kanodia S, Kast WM. Peptide-based vaccines for cancer: realizing their potential. Expert Rev Vaccines 2008; 7: 1533-45.
38. Matsuzaki A, Suminoe A, Hattori H, Hoshina T, Hara T. Immunotherapy with autologous dendritic cells and tumor-specific synthetic peptides for synovial sarcoma. J Pediatr Hematol Oncol 2002; 24: 220-3.
39. Suminoe A, Matsuzaki A, Hattori H, Koga Y, Hara T. Immunotherapy with autologous dendritic cells and tumor antigens for children with refractory malignant solid tumors. Pediatr Transplant 2009; 13: 746-53.
40. Robbins PF, Morgan RA, Feldman SA et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011; 29: 917-24.
41. Holmes JP, Clifton GT, Patil R et al. Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 2011; 117: 463-71.
42. Mittendorf EA, Clifton GT, Holmes JP et al. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 2012; 118: 2594-602.